Почетна › Akutna mijeloidna leukemija › Kalifornija › San Francisco
Kliničke studije za Akutna mijeloidna leukemija u gradu San Francisco, CA
12 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u gradu San Francisco i okolini (u krugu od oko 30 milja). Otvorite studiju da biste videli ko može da učestvuje i kako kontaktirati tim studije.
Zvanični tekst studije (na engleskom)
Tražite učesnike za studiju? Istaknite je na vrhu ove stranice — $99 za 30 dana →
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Тражи се учесникФаза 2
- Kaiser Permanente-San Francisco, San Francisco
- UCSF Medical Center-Parnassus, San Francisco
Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
Тражи се учесникФаза 2
- UCSF Medical Center-Parnassus, San Francisco
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Тражи се учесникФаза 3
- US-San Francisco CA-UCSF, San Francisco
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Тражи се учесникФаза 2
- Kaiser Permanente-San Francisco, San Francisco
- UCSF Medical Center-Parnassus, San Francisco
Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
Тражи се учесникФаза 2
- UCSF Medical Center-Parnassus, San Francisco
Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Тражи се учесникФаза 2
- UCSF Medical Center-Parnassus, San Francisco
A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
Тражи се учесникФаза 1
- UCSF Medical Center-Mission Bay, San Francisco
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Тражи се учесникФаза 3
- UCSF Medical Center-Mission Bay, San Francisco
Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
Тражи се учесникФаза 3
- US-San Francisco CA-UCSF, San Francisco
The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
Тражи се учесникФаза 1/2
- UCSF Medical Center-Mission Bay, San Francisco
Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia
Тражи се учесникФаза 1
- University of California San Francisco, San Francisco
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
Тражи се учесникОпсервациона студија
- UCSF (Peds), San Francisco
Studije za Akutna mijeloidna leukemija u drugim gradovima
- Houston, TX88 студија
- New York City, NY51 студија
- Boston, MA44 студија
- Baldwin Park, CA41 студија
- Seattle, WA40 студија
- Durham, NC34 студија
- Columbus, OH34 студија
- Philadelphia, PA33 студија
- Atlanta, GA30 студија
- Tampa, FL30 студија
- Chicago, IL27 студија
- Los Angeles, CA25 студија
Ostale studije u gradu San Francisco
- Рак простате44 студија
- Рак дојке40 студија
- Рак (све врсте)38 студија
- Немалоклетни карцином плућа37 студија
- Затајење срца29 студија
- Метастатски карцином25 студија
- Рак плућа23 студија
- Меланом21 студија
- Рак јајника20 студија
- Кардиоваскуларне болести20 студија
- Рак панкреаса19 студија
- Глиобластом19 студија
Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.